Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial

NCT05270889 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Gastric Cancer

Interventions

DRUG: Tislelizumab+Zanidatamab

Sponsor

Yonsei University